metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab alone vs. ipilimumab alone	1
	nivolumab plus ipilimumab vs. ipilimumab alone	2
versus ipilimumab followed by nivolumab
	nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab	1
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1
	relatlimab plus nivolumab vs. nivolumab alone	1	-
versus Standard of Care (SoC)
	tremelimumab vs. Standard of Care (SoC)	1